How India Exports Isoniazid to the World

In the United States, isoniazid is approved for the treatment of tuberculosis. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for isoniazid, indicating a competitive generic market. Notably, the combination drug Rifater, containing isoniazid, rifampin, and pyrazinamide, received orphan drug designation on September 12, 1985, and marketing approval on May 31, 1994, for the short-course treatment of tuberculosis. The exclusivity period for Rifater ended on May 31, 2001.

Given the substantial number of Indian exporters (127) and the significant export volume to various countries, including the United States, it is imperative for these exporters to ensure compliance with FDA regulations. This includes adherence to Good Manufacturing Practices (GMP), accurate labeling, and prompt reporting of adverse events. Regular monitoring of FDA communications is essential to stay informed about any import alerts or regulatory changes affecting isoniazid.

In the European Union, isoniazid is authorized for use in tuberculosis treatment. The European Medicines Agency (EMA) oversees the approval and monitoring of medicinal products, including isoniazid. Manufacturers exporting isoniazid to the EU must comply with the EMA's stringent requirements, including obtaining a Certificate of Suitability (CEP) and adhering to the European Pharmacopoeia standards. Additionally, compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory to ensure product quality and safety.

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) regulates medicinal products. Post-Brexit, the UK has established its own regulatory framework, though it closely aligns with EU standards. Exporters must ensure that their products meet MHRA requirements, including obtaining necessary marketing authorizations and adhering to UK-specific GMP standards.

Isoniazid is listed in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its critical role in global health. The 2021 WHO Model List includes isoniazid in various formulations for the treatment of tuberculosis. (iris.who.int)

Several Indian manufacturers have achieved WHO Prequalification for isoniazid, indicating compliance with international quality standards. For instance, Amsal Chem Pvt Ltd's isoniazid was prequalified on September 5, 2017, and Anuh Pharma Ltd.'s isoniazid was prequalified on January 31, 2024. (extranet.who.int)

Isoniazid is also included in major pharmacopoeias such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), providing standardized quality benchmarks for manufacturers and regulators.

In India, isoniazid is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The Drug Price Control Order (DPCO), enforced by the National Pharmaceutical Pricing Authority (NPPA), regulates the pricing of essential medicines, including isoniazid. Manufacturers must adhere to the ceiling prices set by the NPPA to ensure affordability.

For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceutical products. Exporters must ensure compliance with DGFT regulations, including obtaining the necessary NOCs and adhering to export documentation requirements.

Isoniazid, first introduced in the 1950s, is no longer under patent protection, allowing for widespread generic production. This has led to a competitive market with multiple manufacturers producing isoniazid, contributing to its affordability and accessibility globally.

In August 2023, the WHO updated its Model List of Essential Medicines, incorporating new formulations and treatment regimens for tuberculosis, including those involving isoniazid. These updates aim to enhance treatment efficacy and patient adherence. (who.int)

In December 2025, the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending changes to the marketing authorization for Dovprela (pretomanid), a drug used in combination with isoniazid for treating multidrug-resistant tuberculosis. This development reflects ongoing advancements in TB treatment protocols. (ema.europa.eu)

In January 2024, Anuh Pharma Ltd., an Indian manufacturer, received WHO Prequalification for its isoniazid active pharmaceutical ingredient (API), indicating compliance with international quality standards and enhancing its export potential. (extranet.who.int)

In November 2021, the WHO released updated treatment guidelines for isoniazid-resistant tuberculosis, providing new recommendations to improve treatment outcomes for patients with drug-resistant TB strains. (who.int)

In March 2026, the NPPA revised the ceiling price for isoniazid under the DPCO, reflecting changes in production costs and market dynamics. Manufacturers and exporters must adjust their pricing strategies accordingly to remain compliant.

These developments underscore the dynamic nature of the regulatory and market landscape for isoniazid, necessitating continuous monitoring and compliance by stakeholders.

Isoniazid, a critical anti-tuberculosis medication, is predominantly manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) imported from China. This dependency exposes the supply chain to potential disruptions stemming from geopolitical tensions, trade restrictions, or environmental regulations affecting Chinese chemical manufacturing. For instance, during the COVID-19 pandemic, India's pharmaceutical industry faced significant challenges due to interruptions in the supply of KSMs and APIs from China, leading to increased costs and supply chain vulnerabilities.

Recognizing this strategic vulnerability, the Indian government initiated the Production Linked Incentive (PLI) scheme in mid-2020, allocating up to ₹6,940 crore ($955 million) to promote domestic manufacturing of KSMs, drug intermediates, and APIs. The scheme aims to reduce reliance on imports by providing financial incentives to manufacturers of 41 identified products covering 53 APIs over six years.

Our proprietary trade data indicates a high supplier concentration in the export of Isoniazid from India. The top five exporters account for 99.1% of total exports, with LUPIN LIMITED alone contributing 73.9% ($1,675.7 million). This significant concentration poses a single-source risk, as any operational or regulatory issues affecting these key suppliers could disrupt the global supply of Isoniazid.

The PLI scheme's recent inauguration of two greenfield plants in October 2024 marks a step toward reducing import dependence on critical pharmaceutical ingredients. These facilities are set to manufacture essential molecules like Penicillin G, 6-APA, and Clavulanic Acid, which are vital for producing common antibiotics. While this initiative is promising, its immediate impact on diversifying Isoniazid suppliers remains limited.

The global pharmaceutical supply chain is susceptible to geopolitical tensions and shipping disruptions. Recent incidents, such as the attack on the container vessel ONE Majesty in March 2026, have underscored the vulnerabilities of key maritime routes like the Strait of Hormuz. Such events can lead to increased freight and insurance costs, longer transit times, and potential delays in the delivery of pharmaceutical products, including Isoniazid. (glottis.global)

Additionally, the U.S. Pharmacopeia's Medicine Supply Map report from October 2025 highlighted that 41% of key starting materials for U.S.-approved medicines are sourced solely from China. This concentration poses significant risks of disruption due to geopolitical conflicts, export restrictions, or natural disasters, potentially leading to shortages of essential medications like Isoniazid.

• Diversify Supplier Base: Encourage the development of alternative suppliers for Isoniazid and its KSMs to reduce dependency on a limited number of sources.

• Enhance Domestic Production: Support initiatives like the PLI scheme to bolster domestic manufacturing capabilities for APIs and KSMs, thereby decreasing reliance on imports.

• Strengthen Supply Chain Resilience: Implement robust risk assessment and contingency planning to address potential disruptions in the supply chain, including geopolitical and shipping challenges.

• Monitor Regulatory Developments: Stay informed about international regulatory changes and compliance requirements to anticipate and mitigate potential impacts on the supply chain.

• Invest in Logistics Infrastructure: Develop and maintain flexible logistics networks to adapt to changing geopolitical landscapes and ensure the timely delivery of pharmaceutical products.

RISK_LEVEL: MEDIUM